Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study…
News
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical…
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency…
Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update Conference Call on August 10
COPENHAGEN, Denmark, Aug. 04, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) announced today…
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a…
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of…
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events FLORHAM…
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced…
Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
A total of 654 adults and children, age six and older, have been enrolled in…
aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results
Management to host conference call and webcast on August 15th at 5:00 pm EDT /…
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating…
Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – –…
Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10
Company to host an investor conference call and webcast at 4:30pm ET on that day…
Sunshine Biopharma Files Its Second Quarter Report With the SEC
Company Reports Significant Increase in Cash on Hand as a Result of Recent Financings MONTREAL, Aug….
Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) — Apexigen, Inc. (NASDAQ: APGN) a clinical-stage…
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish…
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate…
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events
The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment…
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin…
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially…